BACKGROUND: Pregnane xenobiotic receptor (PXR), a ligand-activated transcription factor, regulates the drug metabolism and transport. Its activation can reduce the efficacy of antineoplastic agents. The aim of this study was to investigate the role of PXR and the relationship between PXR and multidrug resistance-related protein 3 (MRP3) in human colon cancer chemoresistance. RESULTS: The results showed that both the mitochondrial RNA (mRNA) and protein levels of PXR and MRP3 were much higher in colon cancer tissues than that in nonneoplastic tissues by reverse transcriptase polymerase chain reaction and Western blot analysis. MRP3 mRNA was significantly correlated with PXR mRNA in cancerous (P = 0.001) and nonneoplastic (P < 0.001) colon tissues with Pearson correlation test. The expressions of PXR, SP1, and MRP3 were markedly enhanced after rifampicin treatment. On the other hand, the protein level of MRP3 decreased after stable RNA interference of PXR. It also observed that PXR, activated by rifampicin or knocked down via short hairpin RNAs, could enhance or reduce cells resistance to the chemotherapeutic agents through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. CONCLUSIONS: The results suggested that PXR, associated with MRP3, may play an important role in human colon cancer resistance to chemotherapeutics and SP1 may be involved in the induction of MRP3 by PXR activation.
BACKGROUND: Pregnane xenobiotic receptor (PXR), a ligand-activated transcription factor, regulates the drug metabolism and transport. Its activation can reduce the efficacy of antineoplastic agents. The aim of this study was to investigate the role of PXR and the relationship between PXR and multidrug resistance-related protein 3 (MRP3) in humancolon cancer chemoresistance. RESULTS: The results showed that both the mitochondrial RNA (mRNA) and protein levels of PXR and MRP3 were much higher in colon cancer tissues than that in nonneoplastic tissues by reverse transcriptase polymerase chain reaction and Western blot analysis. MRP3 mRNA was significantly correlated with PXR mRNA in cancerous (P = 0.001) and nonneoplastic (P < 0.001) colon tissues with Pearson correlation test. The expressions of PXR, SP1, and MRP3 were markedly enhanced after rifampicin treatment. On the other hand, the protein level of MRP3 decreased after stable RNA interference of PXR. It also observed that PXR, activated by rifampicin or knocked down via short hairpin RNAs, could enhance or reduce cells resistance to the chemotherapeutic agents through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. CONCLUSIONS: The results suggested that PXR, associated with MRP3, may play an important role in humancolon cancer resistance to chemotherapeutics and SP1 may be involved in the induction of MRP3 by PXR activation.
Authors: Edith J Mensah-Osman; Dafydd G Thomas; Michelle M Tabb; Jose M Larios; Dennis P Hughes; Thomas J Giordano; Michelle L Lizyness; James M Rae; Bruce Blumberg; Paul F Hollenberg; Laurence H Baker Journal: Cancer Date: 2007-03-01 Impact factor: 6.860
Authors: Wensheng Chen; Shi-Ying Cai; Shuhua Xu; Lee A Denson; Carol J Soroka; James L Boyer Journal: Am J Physiol Gastrointest Liver Physiol Date: 2007-02-01 Impact factor: 4.052
Authors: George L Scheffer; Marcel Kool; Marcel de Haas; J Marleen L de Vree; Adriana C L M Pijnenborg; Diederik K Bosman; Ronald P J Oude Elferink; Paul van der Valk; Piet Borst; Rik J Scheper Journal: Lab Invest Date: 2002-02 Impact factor: 5.662
Authors: Koji Matsuo; Masato Nishimura; Justin N Bottsford-Miller; Jie Huang; Kakajan Komurov; Guillermo N Armaiz-Pena; Mian M K Shahzad; Rebecca L Stone; Ju Won Roh; Angela M Sanguino; Chunhua Lu; Dwight D Im; Neil B Rosenshien; Atsuko Sakakibara; Tadayoshi Nagano; Masato Yamasaki; Takayuki Enomoto; Tadashi Kimura; Prahlad T Ram; Kathleen M Schmeler; Gary E Gallick; Kwong K Wong; Michael Frumovitz; Anil K Sood Journal: Clin Cancer Res Date: 2011-07-07 Impact factor: 12.531
Authors: Tasmin Reuter; Rolf Warta; Dirk Theile; Andreas D Meid; Juan Pablo Rigalli; Carolin Mogler; Esther Herpel; Niels Grabe; Bernd Lahrmann; Peter K Plinkert; Christel Herold-Mende; Gerhard Dyckhoff; Walter Emil Haefeli; Johanna Weiss Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-07-04 Impact factor: 3.000